Limited EvidencePeptide

LL-37

The human cathelicidin

Antimicrobial Peptide

Last updated: August 2026

Evidence Level: Limited Evidence

Mostly animal data or anecdotal reports, theoretical basis

Regulatory Status: Not approved anywhere. Added to FDA 503A Category 2 in 2023 as cathelicidin LL-37. Investigated as a topical wound treatment; that program did not meet its primary endpoint.

LL-37 is the only cathelicidin humans make, a 37-amino-acid antimicrobial peptide your immune cells release to kill bacteria directly and coordinate wound repair. It is genuinely part of your innate immune system. As a drug, its best-tested use is topical wound healing, where a 148-person phase 2b trial did not beat placebo overall.

How It Works

Your innate immune system does not only send cells to fight infection. It also releases molecules that kill microbes directly, and LL-37 is the main one humans make.

How it kills. LL-37 is positively charged and shaped so that one side is water-loving and the other is fat-loving. Bacterial membranes carry more negative charge than human cell membranes, so LL-37 is drawn to them preferentially, inserts itself, and punches holes in the membrane. Because this is physical disruption rather than a biochemical target, bacteria find it much harder to develop resistance than they do to conventional antibiotics. That property is why LL-37 has attracted so much research attention.

It also disrupts biofilms. Biofilms are protective slime layers bacteria build to shield themselves, and they are a major reason chronic infections resist antibiotics. LL-37 interferes with biofilm formation at concentrations well below what it takes to kill the bacteria outright. This is the basis for most of the chronic-infection marketing.

It is not just an antibiotic. LL-37 also recruits immune cells, promotes new blood vessel growth, and stimulates the migration of skin cells across a wound. This dual role, killing microbes and coordinating repair, is why wound healing was the obvious first clinical target.

What happened in the trial. The HEAL LL-37 study was a phase 2b double-blind randomized placebo-controlled trial in 148 people with hard-to-heal venous leg ulcers, testing topical LL-37 at two concentrations alongside compression therapy. Across the full study population, LL-37 did not significantly improve healing compared with placebo. A subgroup analysis of large refractory ulcers over 10 square centimeters did show a difference in complete healing, 28.8% versus 8.1%.

Read that subgroup result carefully. Subgroup analyses in trials that miss their primary endpoint are hypothesis-generating, not conclusions. They are the single most common source of findings that fail to replicate. It may be a real signal in a population where the peptide has room to help. It may be noise. The trial as designed does not tell you which.

And the vitamin D connection. Your body's own LL-37 production depends on vitamin D signaling, which is one of the more concrete mechanisms linking vitamin D status to infection risk. This is interesting biology and is not evidence that injecting synthetic LL-37 does anything.

Evidence by Outcome

Each claim below is rated using a GRADE-aligned five-tier system. Same molecule, different outcomes, different evidence.

Evidence at a glance

How we grade

Tissue repair / healingLow
Immune functionPreclinical

Want to see how this compares to every other peptide? Browse the full evidence matrix, where every graded claim is grouped by outcome and sorted by certainty.

Tissue repair / healingLow certainty

Accelerates healing of hard-to-heal venous leg ulcers when applied topically.

Population: Adults with hard-to-heal venous leg ulcers receiving compression therapy

Why this rating

A well-designed, multicenter, double-blind, placebo-controlled phase 2b trial of 148 participants did not find a significant healing benefit in the overall population. A pre-specified or post-hoc subgroup of large refractory ulcers did show a difference. Subgroup findings inside a trial that missed its primary endpoint are hypothesis-generating rather than confirmatory, and require replication in a trial designed around that population.

GRADE downgrade factors applied

Inconsistency: Heterogeneous results across studies that cannot be explained, or pending replication.
Imprecision: Wide confidence intervals or small sample size, the estimate could be substantially different.

Supporting studies

Evaluation of LL-37 in healing of hard-to-heal venous leg ulcersRandomized Controlled Trial
Wound Repair and Regeneration2021n=148
No significant benefit overall; a subgroup difference in large refractory ulcers.
DOI: 10.1111/wrr.12977

Reviewed 2026-08-24· Designing Longevity EditorialHow we grade

Immune functionPreclinical certainty

Treats chronic infections or disrupts biofilms in humans.

Population: No human population has been studied for this use.

Why this rating

LL-37 clearly kills bacteria and interferes with biofilm formation in laboratory conditions, and that is the entire basis for how it is marketed for chronic infections, Lyme disease, and biofilm-related illness. We could not identify any controlled human trial of LL-37 for any infectious indication. Laboratory antimicrobial activity is one of the least reliable predictors of clinical benefit, because getting a peptide to the right place at the right concentration in a living body is the hard part.

Supporting studies

LL-37 antimicrobial and antibiofilm activity in vitroIn-Vitro
Broad antimicrobial activity and biofilm inhibition demonstrated in laboratory conditions only.

Reviewed 2026-08-24· Designing Longevity EditorialHow we grade

Potential Benefits

A real component of human innate immunity with well-characterized antimicrobial activity
Kills bacteria by physically disrupting membranes, a mechanism resistance develops against slowly
Disrupts biofilms at concentrations below those needed to kill bacteria
Also promotes wound repair by recruiting immune cells and stimulating new blood vessels
Reached a properly designed phase 2b randomized controlled trial, which most research peptides never do
Active against some bacteria that resist conventional antibiotics, at least in laboratory conditions

Risks & Considerations

Its best-designed trial did not meet its primary endpoint in the overall study population
The positive result was a subgroup analysis in a failed trial, which is the classic setup for a finding that does not replicate
Marketed for chronic infections, Lyme disease, and biofilm conditions with no controlled human trials for any of those uses
LL-37 is a double-edged molecule biologically: it is implicated in inflammatory conditions including psoriasis and rosacea, where too much of it is part of the problem
Systemic injection is a completely different proposition from the topical application that was studied
Can cause significant injection site reactions, since it is a membrane-disrupting molecule
Unregulated supply with no verified purity, and it is placed in FDA Category 2

Dosing Information

The only well-designed human study used topical application at defined concentrations. There is no established dose for injection, which is how it is usually sold.

•The phase 2b trial used topical LL-37 at 0.5mg/mL and 1.6mg/mL alongside compression therapy
•Gray-market protocols suggest subcutaneous injection at roughly 100mcg daily, a route and dose no trial has evaluated
•Injection site reactions are commonly reported and are consistent with a membrane-disrupting peptide
•Short cycles are the norm in clinic practice, again by convention rather than evidence
•We are not recommending a systemic dosing protocol for a peptide studied only topically

Need to mix this from a vial?

Use our reconstitution calculator to get the exact insulin syringe units to draw.

Practical Tips

1Distinguish the topical evidence from the injectable marketing. They are not the same thing at all
2If you have a chronic bacterial infection, this is an infectious disease specialist question. LL-37 has no controlled evidence for that use
3If you have psoriasis or rosacea, be aware that excess LL-37 activity is implicated in those conditions
4Maintaining adequate vitamin D supports your own LL-37 production, which is cheap, safe, and actually evidence-based
5Read the phase 2b result carefully before spending money. Missing a primary endpoint is the headline, not the subgroup

Key Research

Evaluation of LL-37 in healing of hard-to-heal venous leg ulcers: A multicentric prospective randomized placebo-controlled clinical trial

Wound Repair and Regeneration, 2021

Topical LL-37 did not significantly improve healing versus placebo across the full study population. A subgroup of large refractory ulcers over 10 square centimeters showed complete healing in 28.8% versus 8.1% on placebo.

View Study

LL-37 antimicrobial and biofilm activity

Multiple in-vitro studies

LL-37 kills a broad range of bacteria by disrupting membranes and inhibits biofilm formation at sub-lethal concentrations in laboratory conditions.

Want to learn more?

Explore related content and talk to a healthcare provider.

Browse All Treatments Find Your Goal

Always consult a healthcare provider before starting any treatment.This treatment has limited human evidence.

Frequently Asked Questions

What is LL-37?

LL-37 is the only cathelicidin that humans produce, a 37-amino-acid antimicrobial peptide released by immune cells and skin cells. It kills bacteria by physically disrupting their membranes and also helps coordinate wound repair by recruiting immune cells and promoting new blood vessel growth. It is a genuine part of your innate immune system, not a synthetic invention.

Does LL-37 work for chronic infections or Lyme disease?

There is no controlled human trial evidence for any infectious indication, including Lyme disease and biofilm-related conditions. LL-37 does kill bacteria and disrupt biofilms in laboratory dishes, which is the basis for the marketing. Getting a peptide to the right tissue at the right concentration inside a living body is a completely different and much harder problem, and nobody has shown it works.

Did LL-37 fail its clinical trial?

It missed its primary endpoint. The phase 2b HEAL trial tested topical LL-37 in 148 people with hard-to-heal venous leg ulcers and found no significant healing benefit across the full study population. A subgroup of patients with large ulcers over 10 square centimeters did show more complete healing, 28.8% versus 8.1%. Subgroup results from a failed trial are a reason to run another trial, not a reason to conclude the drug works.

Is LL-37 an antibiotic?

It is an antimicrobial peptide, which is a different category. Conventional antibiotics usually hit a specific biochemical target, and bacteria evolve around those targets. LL-37 physically disrupts bacterial membranes, which is much harder to develop resistance to. That is genuinely promising biology. It has not translated into an approved treatment for any infection.

Does vitamin D increase LL-37?

Yes, and this is one of the better-established mechanisms linking vitamin D to immune function. Your body's production of LL-37 is regulated by vitamin D signaling, so low vitamin D means less LL-37 available. Maintaining adequate vitamin D is a cheap, safe, well-supported way to support your own production. That is a completely separate question from whether injecting synthetic LL-37 helps.

Are there risks to taking LL-37?

Beyond the usual unregulated-supply concerns, there is a specific biological caution. LL-37 is a double-edged molecule: excess LL-37 activity is implicated in inflammatory skin conditions including psoriasis and rosacea, where it acts as a driver rather than a fix. It is also a membrane-disrupting molecule, which is why injection site reactions are commonly reported. More is not obviously better here.

New to Peptides?

Learn the basics of peptide therapy, how to inject safely, and what to look for in quality sources.

What Are Peptides? Peptide Safety Guide

Related Peptides

Thymosin Alpha-1Immune-Modulating Peptide

KPVAnti-Inflammatory Tripeptide

BPC-157Cytoprotective Peptide